Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘bempeg’

Hot Topics: What we learned from SITC20 about an emerging class of oncology agents

National Harbor – Missing the Fall colours!

As we get into the final swing of the Fall cancer conference season, at SITC this weekend there was much to think about in terms of early stage oncology drug development.

Still, it did feel rather surreal not to be in Maryland at the Gaylord National Centre in National Harbor for a live meeting this year, especially considering this particular specialist IO meeting tends to be held in a small jam-packed hall with nary an empty seat to be had!

I thought it would be fun to focus on an area which is slowly receiving more attention, with at least one sub category actually beginning to look quite promising indeed…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the SITC annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Waves and waves of T cells

NKTR-214 Cover on Cancer Discovery

In the third part of our mini-series on cytokines, we get down and dirty with another pegylated IL-2 approach, this time from Nektar Therapeutics, including an interview with the PI, Dr Adi Diab from MD Anderson Cancer Centre and CSO, Dr Jonathan Zalevsky.

We’ve certainly had many full ranging discussions and chats with the good gentlemen; here we continue our journey to understand more about the science and underlying biology, as well as key biomarkers of response.

We can also be provocative too and put them on the spot regarding their critics and some of the pointed questions that get bandied about, which certainly makes for interesting reading.  Are they justified?

What should we be looking for when analysing the data?  You can find out for yourselves in the latest expert interview.

Other pertinent topics are also covered including where they’re headed and future data readouts to expect.

To learn more and get a heads up on our latest oncology insights and thought leader interviews, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!